Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gee more BS as I'm expected to believe Elite's generic Percocet will provide zero revenue. Lol indeed. Next
I agree it was BS on Friday and it's still BS today.
Gee and the PPS still isn't in the .02's = LMAO!!!!
Tell me how many sales those Andas will provide in the history of the company????
I'll wait..........
Funny when there was no way in hell I could call a 10 plus bagger at .06 cents.
LMAO; yes I heard the same BS at .06 cents. lol
Tell me again how many Andas Elite filed prior to Nasrat becoming CEO???
I'll wait....
Buy all one can at the existing PPS.
Ahh just more BS I've been hearing since .06 cents. lol lol lol
Agreed the stock is oversold currently.
I agree; .02 cent "SOONS" was BS back then and now.
Buy all one can at the exiting PPS. When the warning letter gets removed the PPS moves up.
Gee you mean Elite's filed more Andas in the last 2 years than in the entirety of the company. Got it. lol
Gee I'd say 4 additional Andas worth the existing generic pipeline. I'll call that savvy and then some.
LMAO; show me on the chart where the PPS will be on the day the warning letter is removed. WHOOPSY!!!
Gee that is total BS - nobody said the stock was in the oversold territory at 57 cents and no proof to the counter will be provided.
I'll wait.......
And when the warning letter gets lifted - time to move UP $$$$$$$$
10 FACTS of LIGHT leading to DOLLARLAND = $$$$$$$$$
1) It's important to keep in mind, and as Nasrat will discuss, our resources are being increasingly focused on our generic and opioid pipeline, and preparing for the launch of the generic products already filed with the FDA, as well as the generics which are licensed currently to Epic that will be coming back to Elite in late 2018, when that license expires.
our business is moving away from this type of revenue stream that is dependent on third parties.
2) the resources which were previously utilized for contract manufacturing were allocated to product development. Instead of making Methadone batches, these resources were used to run batches in products which are under development. In addition, we extended our lab and regulatory personnel to support this greatly increased product development activities.
The level of product development activity is the highest that I've seen since I've been here. And I've been with Elite since 2009.
3) there are three ANDAs already filed and under active review with the FDA. Also several other products in various stages of development that we expect will result in more ANDA filings over the near and mid-terms.
4) SequestOx - We are right now focusing on evaluating the right path forward for us to resolve this issue. Epic is negotiating and engaged with us. We've received several phone calls from them, offering their help and we made the announcement regarding the fat study.
5) Our ER products and pipeline are moving forward - And we are pursuing ER formulations. As a matter of fact, most of the money is in the ER extended release formulation
6) We started our aggressive program of filing one ANDA per quarter in Q3 of 2016. We filed one then and we filed another one in Q4, and a third in Q1 of 2017. We missed Q2 of 2017. We are scheduled to file one in Q3 of this year, so it's going to happen way before the end of this quarter and we are scheduled to file another one in Q4 by December.
7) The FDA has granted us 12-month extension for resubmission. One of my main concerns was if we missed this date by December of this year, which we will - that we will end our PDUFA fee and then we'll have to pay another one. We communicated with the FDA and they give us a 12-month extension. Now we can file any time in 2018 up to and through December 31, 2018 without asking for another extension if needed. And if the results are valid, we can proceed within that timeframe without paying another PDUFA fee.
8) we have many other valuable products that are progressing rapidly right now. At Elite, when we were manufacturing a little more, the number of [entries that I remember on our study] [ph] was about 13. And now, we're up to 50 and growing. And the reason we're growing even though the manufacturing part is not our primary focus and small, is because of all of these projects that are going to lead us within the next couple of years to becoming a seriously viable company. FYI, the total market size of the pipeline products that we are co-developing with SunGen is $6 billion.
9) All Elite needs is about $50 million in profit for our stock to go to dollar land, do the math. For our future growth, Elite pipeline will be the driver. We want to ensure a high rate of revenue growth by aggressively targeting one ANDA filing each quarter. Okay. As I stated earlier, out of the last four quarters we have submitted three ANDAs. We are scheduled to submit one this quarter and one in the quarter after.
10) we have completed the expansion of our manufacturing facility in preparation for our new product approval and launches.
Gee it wasn't BS back then and it isn't now. WHOOPSY!!!!
Exactly Snup!
Clear up the warning letter and get the percocet Anda approved and the SS Elite is a whole different ballgame.
Buy when others are fearful!!
Gee more BS - the newer generics are far from breadcrumbs.
He isn't clueless now - just working at a small pharma with way less structural support. He'll get the warning letter removed and between then and now I'll hear more BS about .02 cent "SOON" and sub penny.
And the chart isn't forward looking it only shows a picture of the past. It doesn't show the PPS when the warning letter gets removed.
The chart - The chart says Elite is in the oversold territory at this point. The RSI is just below 30. One positive PR and the stock moves up considerable from here.
More BS - the real value of the company is 20 cents at minimum on the existing generic pipeline.
Elite will be just fine on their generic pipeline alone. 10-12 products in the works with SunGen already. Just have to remove the warning letter and get the first newer generic approved and the PPS moves up considerably.
Just more BS.........Nasrat dealt with plenty of warning letters while at Actavis. He'l get the warning letter lifted and the BS will move to something else.
The list just continues to get larger and larger:
1) BK
2) RS
3) .02 cent "SOON"
4) Sub penny
5) Elite will never have enough money for a phase 3 trial.
6) SequestOx will be shelved forever.
7) Nasrat will never get the warning letter lifted.
SXCP owns a new state of the art coke manufacturing facility when most other manufacturing plants are old and being retired. Plus the new facility is much more efficient than the older plants. SXCP operates under long term take or pay contracts - none of which terminate before 2020 and most of which last much longer. SXCP's steel customers are the giants of the industry and are creditworthy. Over the long term, SXCP has been reducing debt from $941 million in Q3 2015 to $813 million in Q1 2017. If that 600 million you mention is for debt in the current quarter than I'd say SXCP is doing a solid job of knocking its debt down.
While I haven't looked at when the debt is due plenty of companies have been pushing their debt out further with lower interest rates. I wouldn't be surprised to see SXCP due this if SXC doesn't buy them out within the next 6 months. An SXC will need IMO to offer SXCP 20% higher than the previous buyout price of $17.80. So anything about $21 and I'd bet the buyout goes through this time.
Q1 2017 - First quarter numbers looke very good. In comparison with Q1 2016, EBITDA was up to $50.9 million from $47.3 million. DCF was down to $37.1 million from $45.9 million largely due to the $7 million dollar impact of the corporate cost holiday in Q1 2016. The most variable part of SXCP's business - coal logistics - is doing very well with the Convent terminal experiencing the highest volumes since its acquisition in 2015.
The most recent quarter EBITDA guidance for the full year ($210-220 million). I'm expecting 220 million so I don't see a problem with SXCP's debt load moving forward. In fact the company's numbers were the company's best ever from an operating perspective.
That should answer a few of your questions though not all. Let's call it a start shall we.
Appreciate the questions.
My best,
Couch
Again, let me know how the BS goes when the FDA lifts the warning letter. In the interim, I'll continue buying at the current prices. As that is when Part 2 kicks in.
Gee let me know how that collapsing price per share does on the day Elite PRs that the FDA has lifted their warning letter. On that day the BS I keep hearing will be laughed at by me and many others.
I heard the same BS when I was buying hand over fist at .06 cents prior to Nasrat becoming CEO when "no buying" was happing also. I could give a rats ass what anybody is doing with shares here. SunGen collaboration plus existing Andas in with the FDA makes this stock highly undervalued no amount of BS will change this fact.
I guess investors can see through the daily BS that has been going on for years. The stock continues to be highly undervalued.
Gee you mean penny stocks are risky!!!! WOW!!!!! lol
Nice to hear this Josey!! :)
Some good money made and letting the rest ride.
I'll not argue with a BP or JV partnership with a decent marketing and sales department, however, in the immediate timeframe, Elite needs the warning letter removed for investor confidence.